T1	Participants 62 115	patients with implantable cardioverter defibrillators
T2	Participants 199 285	anti-tachycardia pacing (ATP) and shock-terminated events in patients with implantable
T3	Participants 286 320	cardioverter defibrillators (ICDs)
T4	Participants 651 690	patients with inducible monomorphic VT.
T5	Participants 699 862	A total of 172 patients were randomized to daily treatment with placebo, 35 mg, 75 mg, or 125 mg of oral AZ in this dose-ranging pilot study of patients with ICDs.
T6	Participants 863 1016	The majority of patients had a history of documented remote myocardial infarction and congestive heart failure New York Heart Association class II or III
T7	Participants 1536 1689	Azimilide dihydrochloride may be a safe and effective drug for reducing the frequency of VT and ventricular fibrillation in patients with implanted ICDs.
T8	Participants 1157 1352	The incidence of ICD therapies per patient-year among the placebo group was 36, and it was 10, 12, and 9 among 35 mg, 75 mg, and 125 mg AZ patients, respectively (hazard ratio = 0.31, p = 0.0001)
